Media coverage about OpGen (NASDAQ:OPGN) has been trending positive this week, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. OpGen earned a news sentiment score of 0.31 on Accern’s scale. Accern also gave news headlines about the medical research company an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an impact on the company’s share price in the next few days.

Shares of OpGen (NASDAQ OPGN) traded down 5.09738% during midday trading on Thursday, reaching $0.30701. 1,029,519 shares of the company’s stock traded hands. The stock’s market cap is $13.98 million. The stock has a 50 day moving average of $0.51 and a 200-day moving average of $0.87. OpGen has a 52-week low of $0.28 and a 52-week high of $3.10.

A number of equities analysts have recently commented on OPGN shares. HC Wainwright set a $1.00 price target on shares of OpGen and gave the company a “buy” rating in a research report on Tuesday, July 18th. Zacks Investment Research raised shares of OpGen from a “sell” rating to a “hold” rating in a research report on Wednesday, June 28th. Finally, Dawson James reaffirmed a “buy” rating on shares of OpGen in a research report on Monday, June 19th.

WARNING: This story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/08/03/opgen-nasdaqopgn-earns-daily-coverage-optimism-rating-of-0-31-updated-updated-updated.html.

In other news, Chairman Jven Capital, Llc purchased 1,875,000 shares of the company’s stock in a transaction dated Tuesday, July 18th. The shares were purchased at an average cost of $0.40 per share, for a total transaction of $750,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Timothy C. Dec purchased 65,000 shares of the company’s stock in a transaction dated Tuesday, July 18th. The stock was purchased at an average price of $0.40 per share, for a total transaction of $26,000.00. Following the completion of the purchase, the chief financial officer now owns 118,966 shares in the company, valued at $47,586.40. The disclosure for this purchase can be found here. Company insiders own 53.27% of the company’s stock.

About OpGen

OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.

Insider Buying and Selling by Quarter for OpGen (NASDAQ:OPGN)

Receive News & Stock Ratings for OpGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc. and related stocks with our FREE daily email newsletter.